Anti-cancer information: Dosage of dasatinib, simple understanding of its usage

Dasatinib is an oral tablet indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML who no longer benefit from or are intolerant to other treatments, including imatinib, adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from or are intolerant to other treatments, and adults 1 year and older with Ph+ Children in the chronic phase of CML and children 1 year old and older with newly diagnosed Ph+ ALL combined with chemotherapy. It is not known whether dasatinib is safe and effective in children under one year of age.

The dose of dasatinib is 100 mg once a day in the treatment of chronic phase CML; the dose of dasatinib in the treatment of accelerated phase CML, myeloid or lymphoblastic phase CML or Ph+ ALL is 140 mg once a day. Pediatric patients need to be based on their physical condition. Based on the calculation, the dose for patients weighing between 10 and 19 kg is 40 mg; for patients weighing between 20 and 29 kg, the dose is 60 mg; for patients weighing between 30 and 44 kg, the dose is 70 mg; and for patients weighing at least ≥45 kg, the dose is 100 mg. Based on changes in body weight, the dose is recalculated every 3 months or more frequently if necessary.

Dasatinib can be taken by mouth once daily in the morning or evening with or without food. Tablets should not be crushed, cut, or chewed; they should be swallowed whole. Ask your doctor how to take dasatinib tablets if the patient cannot swallow the tablet whole or if the drug is taken by children. Wear latex or nitrile gloves when handling accidentally crushed or broken tablets to prevent contact with the medication.